Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.59 |
| ▸ | CTSK | P43235 | 6/20 | 0.52 |
| ▸ | CTSS | P25774 | 5/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.46 |
| ▸ | PPARG | P37231 | 4/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1319454 | 1.00 | NAALAD2 (0.59) | NAALAD2FOLH1CTSKCTSSCTSL | |
| SCHEMBL7066210 | 1.00 | NAALAD2 (0.59) | NAALAD2FOLH1CTSKCTSSCTSL | |
| SCHEMBL20745305 | 1.00 | NAALAD2 (0.59) | NAALAD2FOLH1CTSKCTSSCTSL | |
| SCHEMBL13263380 | 1.00 | NAALAD2 (0.59) | NAALAD2FOLH1CTSKCTSSCTSL | |
| SCHEMBL18560556 | 1.00 | NAALAD2 (0.59) | NAALAD2FOLH1CTSKCTSSCTSL | |
| SCHEMBL28804956 | 0.90 | CTSK (0.50) | NAALAD2FOLH1CTSKCTSSCTSL | |
| SCHEMBL28804957 | 0.90 | CTSK (0.50) | NAALAD2FOLH1CTSKCTSSCTSL | |
| SCHEMBL27844888 | 0.89 | CTSK (0.57) | NAALAD2FOLH1CTSKCTSSCTSL | |
| SCHEMBL30174879 | 0.89 | CTSK (0.49) | NAALAD2FOLH1CTSKCTSSCTSL | |
| SCHEMBL13293190 | 0.89 | CTSK (0.49) | NAALAD2FOLH1CTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2023-04-18 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-3889146-A1 | POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3889145-A1 | 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-10947213-B1 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-10696649-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| EP-3668863-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| US-10399957-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2019-09-03 | — | — | US | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| EP-3390389-A1 | POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2018-10-24 | — | — | EP | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| WO-2017106607-A1 | POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | WO | disclosed |
| CN-102093260-B | Stereospecific Synthesis of Piperidine Derivatives | TAIGEN BIOTECHNOLOGY CO LTD | 2014-03-05 | — | — | CN | disclosed |
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | PFIZER INC. | 2012-11-22 | — | — | US | disclosed |
| CN-102093260-A | Stereospecific Synthesis of Piperidine Derivatives | TAIGEN BIOTECHNOLOGY CO LTD | 2011-06-15 | — | — | CN | disclosed |
| US-6277987-B1 | FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS | NOVARTIS AG (CH) | 2001-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | NAALAD2 2202/4885FOLH1 1068/4885CTSK 1523/4885 |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | NAALAD2 2202/4885FOLH1 1068/4885CTSK 1523/4885 |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | NAALAD2 2552/4885FOLH1 1311/4885CTSK 4291/4885 |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | NAALAD2 2202/4885FOLH1 1068/4885CTSK 1523/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | NAALAD2 2552/4885FOLH1 1311/4885CTSK 4291/4885 |
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | NAALAD2 2176/4885FOLH1 1090/4885CTSK 1296/4885 |
| US-20120295923-A1 | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | NAALAD2 22/4885FOLH1 80/4885CTSK 503/4885 |
| US-10947213-B1 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | NAALAD2 2202/4885FOLH1 1068/4885CTSK 1523/4885 |
| US-10399957-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | NAALAD2 2439/4885FOLH1 1269/4885CTSK 1257/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | NAALAD2 2439/4885FOLH1 1269/4885CTSK 1257/4885 |
| US-10696649-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | NAALAD2 2202/4885FOLH1 1068/4885CTSK 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.